PerkinElmer, Inc. (United States) (PKI)
Stock Price Chart
Key Info
| Market Cap | 13.26B |
| Revenue (ttm) | 2.98B |
| Net Income (ttm) | 225.81M |
| Shares Out | 111.39M |
| EPS (ttm) | 2.63 |
| PE Ratio | 45.27 |
| Forward PE | 24.69 |
| Dividend | $0.28 |
| Dividend Yield | 0.24% |
Stock Quote
| Trading Day | Aug 6, 2020 |
| Last Price | $119.05 |
| Previous Close | $122.09 |
| Change ($) | -3.04 |
| Change (%) | -2.49% |
| Day's Open | 122.07 |
| Day's Range | 118.21 - 122.58 |
| Day's Volume | 938,187 |
| 52-Week Range | 62.91 - 123.21 |
More Stats
| Market Cap | 13.26B |
| Enterprise Value | 15.27B |
| Earnings Date (est) | Oct 28, 2020 |
| Ex-Dividend Date | Jul 16, 2020 |
| Shares Outstanding | 111.39M |
| Float | 104.97M |
| EPS (basic) | 2.04 |
| EPS (diluted) | 2.63 |
| FCF / Share | 3.17 |
| Dividend | $0.28 |
| Dividend Yield | 0.24% |
| Earnings Yield | 2.21% |
| FCF Yield | 2.65% |
| Payout Ratio | 13.70% |
| Shares Short | 2.78M |
| Short Ratio | 3.03 |
| Short % of Float | 5.09% |
| Beta | 1.42 |
| PE Ratio | 45.27 |
| Forward PE | 24.69 |
| P/FCF Ratio | 37.68 |
| PS Ratio | 4.46 |
| PB Ratio | 4.59 |
| Revenue | 2.98B |
| Operating Income | 353.33M |
| Net Income | 225.81M |
| Free Cash Flow | 351.89M |
| Net Cash | -2.00B |
| Net Cash / Share | -18.00 |
| Gross Margin | 47.63% |
| Operating Margin | 11.87% |
| Profit Margin | 7.80% |
| FCF Margin | 11.82% |
| ROA | 4.53% |
| ROE | 10.37% |
| ROIC | 10.50% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,884 | 2,778 | 2,257 | 2,116 | 2,105 | 2,070 | 2,158 | 2,105 | 1,919 | 1,702 |
| Revenue Growth | 3.8% | 23.08% | 6.69% | 0.51% | 1.69% | -4.07% | 2.49% | 9.73% | 12.74% | - |
| Gross Profit | 1,396 | 1,341 | 1,074 | 1,014 | 964 | 935 | 976 | 962 | 848 | 759 |
| Operating Income | 362 | 324 | 296 | 295 | 251 | 165 | 228 | 103 | 91.13 | 158 |
| Net Income | 228 | 238 | 293 | 234 | 212 | 158 | 167 | 69.94 | 7.66 | 391 |
| Shares Outstanding | 111 | 111 | 110 | 110 | 112 | 113 | 112 | 115 | 113 | 118 |
| Earnings Per Share | 2.04 | 2.13 | 2.64 | 2.12 | 1.87 | 1.39 | 1.47 | 0.61 | 0.07 | 3.31 |
| EPS Growth | -4.23% | -19.32% | 24.53% | 13.37% | 34.53% | -5.44% | 140.98% | 771.43% | -97.89% | - |
| Dividend Per Share | 0.28 | 0.28 | 0.35 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 |
| Dividend Growth | 0% | -20% | 25% | 0% | 0% | 0% | 0% | 0% | 0% | - |
| Operating Cash Flow | 363 | 311 | 288 | 351 | 287 | 282 | 159 | 152 | 225 | 164 |
| Capital Expenditures | -76.33 | -93.25 | -39.09 | -31.70 | -28.22 | -24.62 | 13.22 | -42.40 | -30.14 | -22.63 |
| Free Cash Flow | 287 | 218 | 249 | 319 | 259 | 257 | 172 | 110 | 195 | 142 |
| Cash & Equivalents | 192 | 163 | 202 | 359 | 238 | 175 | 173 | 171 | 142 | 420 |
| Total Debt | 2,220 | 1,891 | 2,006 | 1,046 | 1,013 | 1,046 | 935 | 941 | 945 | 426 |
| Net Cash / Debt | -2,029 | -1,728 | -1,804 | -687 | -775 | -872 | -761 | -769 | -803 | -6.17 |
| Assets | 6,539 | 5,976 | 6,091 | 4,277 | 4,166 | 4,128 | 3,947 | 3,902 | 3,856 | 3,209 |
| Liabilities | 3,725 | 3,391 | 3,588 | 2,123 | 2,056 | 2,085 | 1,952 | 1,962 | 2,013 | 1,284 |
| Book Value | 2,814 | 2,585 | 2,503 | 2,154 | 2,110 | 2,042 | 1,994 | 1,940 | 1,842 | 1,925 |
Company Profile
Company Details
| Full Name | PerkinElmer, Inc. (United States) |
| Country | United States |
| Employees | 13,000 |
| CEO | Prahlad Ramadhar Singh |
Stock Information
| Ticker Symbol | PKI |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NYSE: PKI |
Description
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.